Neflamapimod: Ph IIa Study 302 data

The double-blind, Dutch Phase II Study 302 in 15 evaluable patients ages 60-85 with mild cognitive impairment (MCI) due to AD or mild AD showed that twice-daily oral neflamapimod led to a >7% reductio...